ERBB2 and breast carcinoma: Pertuzumab, a recombinant humanized monoclonal anti-HER2 antibody, sterically blocks HER2 heterodimerization with other HER receptors, especially HER3, and was approved by the FDA in 2012 for breast cancer therapy12.